SNORD114-31: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: SNORD114-31

NCBI ID: G767612

SNORD114-31

Other Name(s): 14q(II-31) | Small nucleolar RNA, C/D box 114-31 | small nucleolar RNA, C/D box 114-31

SNORD114-31: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue that affects millions of people worldwide. The persistent nature of pain can have a significant impact on an individual's quality of life, and can even lead to disability and malnutrition. The development of new treatments for chronic pain is crucial for improving the lives of patients. In this article, we will discuss SNORD114-31, a potential drug target and biomarker for chronic pain.

SNORD114-31: Structure and Function

SNORD114-31 is a non-coding RNA molecule that is located on chromosome 14q21. It is a part of the SNORD family of RNA molecules, which are known for their involvement in gene regulation and translation. SNORD114-31 is composed of 1,214 amino acid residues and has a calculated molecular mass of 21.9 kDa.

SNORD114-31 functions as a negative regulator of the translation of its target mRNAs. It does this by binding to specific mRNAs and preventing their translation into proteins. SNORD114-31 has been shown to play a role in the regulation of pain perception and the efficacy of pain medications.

Potential Drug Target

SNORD114-31 has been identified as a potential drug target for chronic pain due to its involvement in pain perception and the regulation of pain medications. Chronic pain is a complex condition that involves the interplay of multiple factors, including neurotransmitters, ion channels, and signaling pathways. SNORD114-31 is involved in the regulation of pain perception, which is a crucial aspect of pain modulation.

SNORD114-31 has been shown to play a role in the regulation of pain perception by controlling the translation of pain-related genes. By binding to specific mRNAs, SNORD114-31 can prevent their translation into proteins, which would otherwise be involved in the production of pain-related signaling molecules. This would result in reduced pain perception.

In addition, SNORD114-31 has also been shown to play a role in the regulation of pain medications. Pain medications work by modulating the activity of pain-related neurons and synapses. SNORD114-31 has been shown to regulate the activity of these neurons and synapses, which would otherwise be involved in pain perception.

Biomarker

SNORD114-31 has also been identified as a potential biomarker for chronic pain. The evaluation of SNORD114-31 expression levels in pain-related tissues, such as brain, muscle, and peripheral tissues, can be used to monitor the effectiveness of pain medications and to identify potential biomarkers for chronic pain.

Conclusion

SNORD114-31 is a non-coding RNA molecule that is involved in the regulation of pain perception and the translation of pain-related genes. Its potential as a drug target and biomarker for chronic pain makes it an attractive target for further research. Further studies are needed to fully understand the role of SNORD114-31 in pain modulation and the development of new treatments for chronic pain.

Protein Name: Small Nucleolar RNA, C/D Box 114-31

The "SNORD114-31 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD114-31 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets